Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 3

1(16.7%)

Early Phase 1

1(16.7%)

Phase 1

1(16.7%)

6Total

N/A(3)

Phase 3(1)

Early Phase 1(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02492620Phase 3Completed

Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

Role: lead

NCT00785629Not ApplicableCompleted

A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD

Role: lead

NCT01475760Not ApplicableCompleted

A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease

Role: lead

NCT01319578Not ApplicableCompleted

PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum

Role: lead

NCT01311973Completed

Salivary Phosphorus and Level of Kidney Function

Role: lead

NCT01341691Early Phase 1Completed

Phosphate Binding of Chitosan Chewing Gum in Patients With Chronic Kidney Disease (CKD)

Role: lead

NCT01057108Phase 1Completed

Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia

Role: lead

All 7 trials loaded